ARQULE INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-11-09: Form 8-K; Period of report 2017-11-09; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2017-11-08: Form 8-K; Period of report 2017-11-03; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 1.01.
- 2017-10-16: Form 8-K; Period of report 2017-10-11; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; Details 1.01.
- 2017-09-29: Form 8-K; Period of report 2017-09-27; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 8.01 Other Events; Details 3.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2017-11-09 | 8-K | 2017-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2017, ArQule, Inc. (the “Registrant”) issued a press release announcing its results of operations for the third quarter ended September 30, 2017. | tv479029_8k.htm |
| 2017-11-08 | 8-K | 2017-11-03 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 The information set forth in Item 1.01 related to the Offering is incorporated by reference into this Item 3.02. 3.03 On November 7, 2017, in connection with the closing of the Offering, the Company filed a Certificate of Designations for the Shares with the Delaware Secretary of State. 5.02 Effective as of November 7, 2017, the Board of Directors (the “Board”) increased the number of directors by one and appointed Ran Nussbaum as a director, with a term expiring at the annual meeting of stockholders to be held in 2018. 8.01 On November 8, 2017, the Company issued a press release announcing the Offering, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference into this Item 8.01. | tv478922_8k.htm |
| 2017-10-16 | 8-K | 2017-10-11 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 The information set forth in Item 1.01 related to the Offering is incorporated by reference into this Item 3.02. 8.01 On October 16, 2017, the Company issued a press release announcing the Offering, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference into this Item 8.01. | tv476956_8k.htm |
| 2017-09-29 | 8-K | 2017-09-27 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 8.01 Other Events | 3.01 As described below, ArQule, Inc., a Delaware corporation (the "Company"), has been communicating with The Nasdaq Stock Market LLC ("Nasdaq") regarding an issue of inadvertent non-compliance with Nasdaq Listing Rule 5635(c) (Shareholder Approval of Equity Compensation). 8.01 The information set forth in Item 3.01 is incorporated by reference herein. | v476237_8k.htm |
| 2017-08-04 | 8-K | 2017-08-04 | 2.02 Results of Operations and Financial Condition | 2.02 On August 4, 2017, ArQule, Inc. (the “Registrant”) issued a press release announcing its results of operations for the second quarter ended June 30, 2017. | t1700479_8k.htm |
| 2017-07-26 | 8-K | 2017-07-20 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | t1700461_8k.htm |
| 2017-05-24 | 8-K | 2017-05-23 | 5.07 Submission of Matters to a Vote of Security Holders | t1700356_8k.htm | |
| 2017-05-03 | 8-K | 2017-05-03 | 2.02 Results of Operations and Financial Condition | 2.02 On May 3, 2017, ArQule, Inc. (the “Registrant”) issued a press release announcing its results of operations for the first quarter ended March 31, 2017. | t1700271_8k.htm |
| 2017-04-11 | 8-K | 2017-04-11 | 8.01 Other Events | 8.01 ArQule, Inc. (the “Registrant”) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application to conduct a phase 1 clinical trial with ARQ 531 in patients with B-cell malignancies who are refractory to other therapeutic options. | t1700221_8k.htm |
| 2017-04-10 | 8-K | 2017-04-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 4, 2017, the Compensation, Nominating and Governance Committee (the “Committee”) approved a new stock-based incentive and retention program for certain senior executives. | t1700220_8k.htm |
| 2017-03-27 | 8-K | 2017-03-27 | 8.01 Other Events | 8.01 ArQule, Inc. (the “Registrant”) today reported that its partner, Kyowa Hakko Kirin, announced top-line results of the JET-HCC Phase 3 trial of tivantinib in Japan, and that the trial did not meet its primary endpoint of progression free survival. | t1700188_8k.htm |
| 2017-03-07 | 8-K | 2017-03-07 | 2.02 Results of Operations and Financial Condition | 2.02 On March 7, 2017, ArQule, Inc. (the “Registrant”) issued a press release announcing its results of operations for the fiscal quarter and year ended December 31, 2016. | t1700146_8k.htm |
| 2017-02-17 | 8-K | 2017-02-17 | 8.01 Other Events | 8.01 ArQule, Inc. (the “Registrant”) and Daiichi Sankyo today announced that the METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma (HCC) did not meet its primary endpoint of improving overall survival. | t1700120_8k.htm |
| 2017-01-10 | 8-K | 2017-01-06 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 On January 6, 2017, ArQule, Inc. (the "Company"), Oxford Finance LLC, as collateral agent and a lender (the "Lender"), and any additional lenders that may become parties thereto, entered into a loan and security agreement (the “Loan Agreement”). 3.02 The Company relied on the exemption from registration contained in Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D, in connection with the issuance of the Lender Warrants in connection with the Loan Agreement. | t1700016_8k.htm |